DOI QR코드

DOI QR Code

Pretreatment Serum Albumin Level is an Independent Prognostic Factor in Patients with Stage IIIB Non-Small Cell Lung Cancer: A Study of the Turkish Descriptive Oncological Researches Group

  • Tanriverdi, Ozgur (Department of Medical Oncology, Sitki Kocman University Faculty of Medicine) ;
  • Avci, Nilufer (Department of Medical Oncology, State Hospital) ;
  • Oktay, Esin (Department of Medical Oncology, Adnan Menderes University Faculty of Medicine) ;
  • Kalemci, Serdar (Department of Chest Diseases, Sitki Kocman University Faculty of Medicine) ;
  • Pilanci, Kezban Nur (Department of Medical Oncology, Bilim University Faculty of Medicine) ;
  • Cokmert, Suna (Department of Medical Oncology, Kent Hospital) ;
  • Menekse, Serkan (Department of Medical Oncology, Celal Bayar University Faculty of Medicine) ;
  • Kocar, Muharrem (Department of Medical Oncology, Education and Research Hospital) ;
  • Sen, Cenk Ahmet (Department of Medical Oncology, Izmir University Medical Park Hospital) ;
  • Akman, Tulay (Tepecik Education and Research Hospital) ;
  • Ordu, Cetin (Department of Medical Oncology, Bilim University Faculty of Medicine) ;
  • Goksel, Gamze (Department of Medical Oncology, Celal Bayar University Faculty of Medicine) ;
  • Meydan, Nezih (Department of Medical Oncology, Adnan Menderes University Faculty of Medicine) ;
  • Barutca, Sabri (Department of Medical Oncology, Adnan Menderes University Faculty of Medicine)
  • Published : 2015.09.02

Abstract

Background: Several prognostic factors have been studied in NSCLC, although it is unknown which is most useful. In this study, we aimed to investigate whether pre-treatment serum albumin level has prognostic value in patients with Stage IIIB NSCLC. Materials and Methods: This cross-sectional study included a total of 204 patients with Stage IIIB NSCLC who met the inclusion criteria. Pre-treatment serum albumin levels and demographic, clinical, and histological characteristics, as well as laboratory variables were recorded. A cut-off value was defined for serum albumin level and the patients were stratified into four groups on thios basis. Results: The majority of the patients was males and smokers, with a history of weight loss, and squamous histological type of lung cancer. The mean serum albumin level was $3.2{\pm}1.7g/dL$ (range, 2.11-4.36 g/dL). A cut-off value 3.11 g/dL was set and among the patients with a lower level, 68% had adenocarcinoma and 82% were smokers. The patients with low serum albumin levels had a lower response rate to e first-line chemotherapy with a shorter progression-free survival and overall survival. Multivariate analysis showed that low serum albumin level was an independent poor prognostic factor for NSCLC. Conclusions: This study results suggest that low serum albumin level is an independent poor prognostic factor in patients with Stage IIIB NSCLC, associated with reduction in the response rate to first-line therapy and survival rates.

References

  1. Albain KS, Crowley JJ, LeBlanc M, et al (1991). Survival determinants in extensive-stage non-small cell lung cancer: the southwest oncology group experience. J Clin Oncol, 9, 1618-26.
  2. Arinc S, Ece F, Ertugrul M, et al (2009). Prognostic factors of elderly and young advanced stage NSCLC cases. South Med J, 102, 1019-22. https://doi.org/10.1097/SMJ.0b013e3181b66b11
  3. Berghmans T, Mascaux C, Haller A, et al (2008). EGFR, TTF-1, and Mdm2 expression in stage III non-small cell lung cancer: a positive association. Lung Cancer, 62, 35-44. https://doi.org/10.1016/j.lungcan.2008.02.003
  4. Berghmans T, Paersmans M, Sculier JP (2011). Prognostic factors in stage III non-small cell lung cancer: a review on contventional, metabolic and new biological variables. Ther Adv Med Oncol, 3, 127-38. https://doi.org/10.1177/1758834011401951
  5. Betticher DC, Hsuschmitz SF, Totsch M, et al (2006). Swiss group for clinical cancer research (SAKK). Prognostic factors affecting long-term outcomes in patients with resected stage IIIA, pN2 non-small cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer, 94, 1099-106. https://doi.org/10.1038/sj.bjc.6603075
  6. Dewys WD, Begg C, Lavin PT, et al (1980). Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern cooperative oncology group. Am J Med, 69, 491-7. https://doi.org/10.1016/S0149-2918(05)80001-3
  7. Espinosa E, Feliu J, Zamora P, et al (1995). Serum albumin and other prognostic factors related to response and survival in patients with advanced non-small cell lung cancer. Lung Cancer, 12, 67-76. https://doi.org/10.1016/0169-5002(95)00407-R
  8. Fatzinger P, DeMeester TR, Darakjian H, et al (1984). The use of serum albumin for further classification of Stage III nonoat cell lung cancer and its therapeutic implications. Ann Thorac Surg, 37, 115-22. https://doi.org/10.1016/S0003-4975(10)60297-4
  9. Fearon KCH, Falconer JS, Slater C, et al (1998). Albumin synthesis rates are not decreased in hypoalbuminemic cachectic cancer patients with an ongoing acute phase protein response. Ann Surg, 227, 249-54. https://doi.org/10.1097/00000658-199802000-00015
  10. Finkelstein DM, Ettinger DS, Ruckdeschel JC (1986). Long-term survivors in metastatic non-small cell lung cancer: an eastern cooperative oncology group study. J Clin Oncol, 4, 702-9.
  11. Forrest LM, McMillan DC, McArdle CS, et al (2003). Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small cell lung cancer. Br J Cancer, 89, 1028-30. https://doi.org/10.1038/sj.bjc.6601242
  12. Forrest LM, McMillan DC, McArdle CS, et al (2005). A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small cell lung cancer. Br J Cancer, 92, 1834-6. https://doi.org/10.1038/sj.bjc.6602591
  13. Gagnon B, Agunlik JS, Gioulbasanis I, et al (2013). Montreal prognostic score. Estimating survival of patients with nonsmall cell lung cancer using clinical biomarkers. Br J Cancer, 109, 2066-71. https://doi.org/10.1038/bjc.2013.515
  14. Gupta D, Lammersfeld C, Vashi PG, et al (2009). Is serum albumin an independent predictor of survival in ovarian cancer? Clin Ovarian Cancer, 2, 52-6. https://doi.org/10.3816/COC.2009.n.008
  15. Gupta D, Lis CG (2010). Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J, 9, 69. https://doi.org/10.1186/1475-2891-9-69
  16. Hoang T, Xu R, Schiller JH, et al (2005). Clinical model to predict in chemo-naive patients with advanced non-small cell lung cancer treated with third-generation chemotherapy regimend based on Eastern cooperative oncology group data. J Clin Oncol, 23, 175-83. https://doi.org/10.1200/JCO.2005.04.177
  17. Jafri SH, Shi R, Mills G (2013). Advanced lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review. BMC Cancer, 13, 158-67. https://doi.org/10.1186/1471-2407-13-158
  18. Jin Y, Y, Zhao L, Peng F (2013). prognostic impact of serum albumin levels on the recurrence of stage I non-small cell lung cancer. Clinics, 68, 686-93. https://doi.org/10.6061/clinics/2013(05)17
  19. Kasymjanova G, MacDonald N, Agulnik JS, et al (2010). The predictive value of pre-treatment inflammatory markers in advanced non-small cell lung cancer. Curr Oncol, 14, 52-8.
  20. Kaya V, Yildirim M, Demirpence O, et al (2013). Prognostic significance of basic laboratıry methods in non-small cell lung cancer. Asian Pac J Cancer Prev, 14, 5473-6. https://doi.org/10.7314/APJCP.2013.14.9.5473
  21. Ku JH, Kim M, Choi WS, et al (2014). Preoperative serum albumin as a prognostic factor in patients with upper urinary tract urothelial carcinoma. Int Braz J Urol, 40, 753-62. https://doi.org/10.1590/S1677-5538.IBJU.2014.06.06
  22. Lai SL and Perng RP (1998). Impact of nutritional status on the survival of lung cancer patients. Zhonghua Yi Xue Za Zhi (Taipei), 61, 134-140.
  23. Leung EY, Scott HR, McMillan DC (2012). Clinical utility of the pretreatment Glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer. J Thorac Oncol, 7, 655-62. https://doi.org/10.1097/JTO.0b013e318244ffe1
  24. Maestu I, Pastor M, Gomez-Codina J, et al (1997). Pretreatment prognostic factors for survival in small cell lung cancer: a new prognostic index and validation of three known prognostic indices on 341 patients. Ann Oncol, 8, 547-53. https://doi.org/10.1023/A:1008212826956
  25. Margarson MP, Soni N (1998). Serum albumin: touchstone or totem? Anaesthesia, 53, 789-803. https://doi.org/10.1046/j.1365-2044.1998.00438.x
  26. Matsunuma R, Tanbo Y, Asai N, et al (2014). Prognostic factors in patients with terminal stage lung cancer. J Palliat Med, 17, 189-94. https://doi.org/10.1089/jpm.2013.0448
  27. McMillan DC, Watson WS, O'Gorman P, et al (2001). Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer, 39, 210-3. https://doi.org/10.1207/S15327914nc392_8
  28. O'Gorman P, McMillan DC, McArdle CS (1998). Impact of weight loss, appetite, and the inflammatory response on quality of life in gastrointestinal cancer patients. Nutr Cancer, 32, 76-80. https://doi.org/10.1080/01635589809514722
  29. O'Gorman P, McMillan DC, McArdle CS (2000). Factors predicting survival of advanced gastrointestinal cancer patients with weight loss. Nutr Cancer, 37, 36-40. https://doi.org/10.1207/S15327914NC3701_4
  30. Paesmans M, Sculier JP, Libert P, et al (1995). Prognostic factors for survival in advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. the European lung cancer working party. J Clin Oncol, 13, 1221-30.
  31. Seculier JP, Chansky K, Crowley JJ, et al (2008). The impact of additional prognostic factors on survival and their relationship with the anatomical extend of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and proposal for the 7th Edition. J Thorac Oncol, 3, 457-66. https://doi.org/10.1097/JTO.0b013e31816de2b8
  32. Siegel R, Ma J, Zou Z, Jemal A (2014). Cancer statistics, 2014. CA Cancer J Clin, 64, 9-29. https://doi.org/10.3322/caac.21208
  33. Simons JPFHA, Schols AMWJ, Buurman WA, et al (1999). Weight loss and low body cell mass in males with lung cancer: relationship with systemic inflammation, acutephase response, resting energy expenditure, and catabolic and anabolic hormones. Clin Sci, 97, 215-23. https://doi.org/10.1042/cs0970215
  34. Tanriverdi O, Cokmert S, Oktay E, et al (2014). Prognostic significance of the baseline serum uric acid level in non-small cell lung cancer patients treated with first-line chemotherapy: a study of the Turkish descriptive oncological researches group. Med Oncol, 31, 217. https://doi.org/10.1007/s12032-014-0217-z
  35. Trape J, Montesinos J, Catot S, et al (2012). A prognostic score based on clinical factors and biomarkers for advanced nonsmall cell lung cancer. Int J Biol Markers, 27, 257-62. https://doi.org/10.5301/JBM.2012.9314
  36. Ulas A, Paksoy-Turkoz F, Silay K, et al (2014). A laboratory prognostic index model for patients with advanced non-small cell lung cancer. PLoS ONE, 9, 114471. https://doi.org/10.1371/journal.pone.0114471
  37. von Meyenfeldt M (2005). Cancer-associated malnutrition: an introduction. Eur J Oncol Nurs, 9, S35-8. Win T, Sharples L, Groves AM, et al (2008). Predicting survival in potentially curable lung cancer patients. Lung, 186, 97-102. https://doi.org/10.1007/s00408-007-9067-1
  38. Zhang P, Xi M, Li QQ, et al (2014). The modified Glasgow Prognostic Score is an independent prognostic factor in patients with inoperable thoracic esophageal squamous cell carcinoma undergoing chemotherapy. J Cancer, 5, 689-95. https://doi.org/10.7150/jca.9569

Cited by

  1. Glasgow prognostic score predicts prognosis of non-small cell lung cancer: a meta-analysis vol.5, pp.1, 2016, https://doi.org/10.1186/s40064-016-2093-9
  2. The prognostic significance of preoperative serum albumin in urothelial carcinoma: a systematic review and meta-analysis vol.38, pp.4, 2018, https://doi.org/10.1042/BSR20180214